RTP Mobile Logo
Select Publications

Adil Daud, MD

Amaria RN et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018;24(11):1649-54. Abstract

Amaria RN et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: A single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 2018;19(2):181-93. Abstract

Blank CU et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018;24(11):1655-61. Abstract

Huang AC et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 2019;25(3):454-61. Abstract

Long GV et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF V600 mutation-positive melanoma (NeoCombi): A single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol 2019;20(7):961-71. Abstract

Menzies AM et al. Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). ASCO 2019;Abstract 9503.

Rozeman EA et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019;20(7):948-60. Abstract

Michael Postow, MD

Bowyer S et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 2016;114(10):1084-9. Abstract

Davies MA et al. Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017;18(7):863-73. Abstract

Larkin J et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381(16):1535-46. Abstract

Pires da Silva I et al. Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI + PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. ASCO 2020;Abstract 10005.

Robert C et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019;381(7):626-36. Abstract

Zimmer L et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer 2017;75:47-55. Abstract

Hussein Tawbi, MD, PhD

A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients with metastatic melanoma and BRAF mutation. NCT02631447

Ascierto PA et al. First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study). ESMO 2020;Abstract LBA45.

Davies MA et al. COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant (mut) melanoma brain metastases (MBM). ASCO 2017;Abstract 9506.

Johnson DB et al. Sequencing treatment in BRAFV600 mutant melanoma: Anti-PD-1 before and after BRAF inhibition. J Immunother 2017;40(1):31-35. Abstract

Jeffrey S Weber, MD, PhD

Blank CU et al. First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. ASCO 2020;Abstract 10002.

Eggermont AM et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. ASCO 2020;Abstract 10000.

Hauschild A et al. Long-term benefit of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected stage III BRAF V600-mutant melanoma: Five-year analysis of COMBI-AD. ASCO 2020;Abstract 10001.

Weber J et al. Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. ESMO 2020;Abstract 1076O.